askb589
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Nov 15, 2020 (NCT04632108)
Timeline
Indications
Mechanism of action
- Claudin-18INHIBITOR
CLDN18 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06206733 | Phase 3 | Jan 25, 2024 | AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
| NCT05632939 | Phase 1/Phase 2 (Phase 2) | Dec 12, 2022 | AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
| NCT04632108 | Phase 1/Phase 2 (Phase 2) | Nov 15, 2020 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Aosaikang Pharmaceutical Co., Ltd. | For profit | 3 | 1 | 2 | 2020 |
| AskGene Pharma, Inc. | For profit | 2 | 2 | 2 | 2022 |
2 organizations
Page 1 / 1